semaglutide la Hiltzik: Why health insurers won't pay for these miracle weight-loss drugs Weight Loss Wednesday: Low-cost weight

However, individuals who have type 2 diabetes alongside a need to minimise weight gain or promote weight loss may benefit from GLP-1/GIP therapy and its dual impact on type 2 diabetes management and weight loss

Clinical use should remain conservative and individualized

A Highly Effective Treatment for Obesity To further compliance, Knudsen and a team of Novo chemists led by Jesper Lau and Thomas Kruse set out to make a GLP-1 receptor agonist that could be administered once weekly (22)

Key takeaways Nausea is the most common side effect of semaglutide, affecting between 20% to 50% of people taking Ozempic, Wegovy, or Rybelsus